Embecta has pursued strategic corporate development initiatives and targeted acquisitions since becoming an independent publicly traded enterprise to expand its medical device pipeline. Notably, the company acquired VeruVis, a medical technology developer, to bolster its portfolio with innovative infusion set technologies designed to improve continuous subcutaneous insulin infusion therapy for patients managing diabetes.